Background. Multiple sclerosis (MS) is an autoimmune inflammatory disease of central nervous system (CNS). MS affects quality of Life (QOL) due to physical disability and other associated problems. Disease-modifying agents like interferon beta (IFNB) have been widely utilized in this patient population; however, their frequency, route of administration, side effects, high cost, and also the que...

AIM Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This study aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-β formulations in MS patients. MATERIALS & METHODS In this study, blood samples were collected from 70 MS patients undergoin...

INTRODUCTION Multiple sclerosis is a chronic and degenerative neurological disease characterized by loss of myelin sheath of some neurons in brain and spinal cord. It is associated with high economic burden due to premature deaths and high occurrence of disabilities. The aim of the current study was to determine cost effectiveness of two major products of interferon 1a in patients with relapsin...

BACKGROUND Disease-modifying drugs (DMDs) are a significant expenditure for treating multiple sclerosis (MS). However, there is limited report on assessment of the cost-utility of DMDs compared with symptom management in the presence of long-term data. This study aimed to assess the lifetime cost-utility from the Iranian healthcare perspectives of 4DMDs relative to symptom management alone in p...

Treatment with interferon beta (IFN-β) induces the production of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in patients with multiple sclerosis (MS). NAbs against IFN-β are associated with a loss of IFN-β bioactivity and decreased clinical efficacy of the drug. The objective of this study was to evaluate the incidence and the prevalence of binding antibodies (BAbs) and neutral...

conclusions this study showed that ifnβ-1a decreased oxidant impacts in ms patients, but had no influence in improving mitochondrial dysfunction. results in the patients group (30 patients), a significant difference was observed in their measured biochemical factors in comparison to the control group (p = 0.001), however, after six months of using ifnβ-1a, only mda was shown in the main (p = 0....

patients and methods in this study, a total of 92 patients with relapsing-remitting multiple sclerosis (rrms) were randomly allocated into three equal groups; each treatment group received one of the foregoing drugs (cinnovexr, rebif and betaferon) for one year. at the beginning and end of the study, patients ‘ edss was measured and compared. results in this study, the relative frequency of fem...